Last reviewed · How we verify
losartan and HCTZ
Losartan blocks angiotensin II receptors to relax blood vessels, while HCTZ increases sodium and water excretion to reduce blood volume, together lowering blood pressure.
Losartan blocks angiotensin II receptors to relax blood vessels, while HCTZ increases sodium and water excretion to reduce blood volume, together lowering blood pressure. Used for Hypertension, Reduction of cardiovascular risk in hypertensive patients.
At a glance
| Generic name | losartan and HCTZ |
|---|---|
| Also known as | Hyzaar, Azor, Hydrochlorothiazide, Spironolactone |
| Sponsor | InVasc Therapeutics, Inc. |
| Drug class | Angiotensin II receptor blocker + thiazide diuretic combination |
| Target | AT1 receptor (losartan); sodium-chloride cotransporter (HCTZ) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Losartan is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from binding to AT1 receptors on vascular smooth muscle, causing vasodilation and reduced peripheral resistance. Hydrochlorothiazide (HCTZ) is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, promoting urinary sodium and water loss and decreasing circulating blood volume. The combination provides complementary antihypertensive effects through different mechanisms.
Approved indications
- Hypertension
- Reduction of cardiovascular risk in hypertensive patients
Common side effects
- Dizziness
- Fatigue
- Hyperkalemia (losartan component)
- Hypokalemia (HCTZ component)
- Hyperglycemia
- Hyperuricemia
- Cough
Key clinical trials
- ACES - ACE Inhibitors Combined With Exercise for Seniors With Hypertension (PHASE2)
- Transforming Hypertension Treatment in Nigeria Using a Type II Hybrid, Interrupted Time Series Design (NA)
- Efficacy and Safety of a Single-pill Fixed Combination of Sufficient Losartan/Hydrochlorothiazide in Chinese Hypertensive Patients (PHASE4)
- Efficacy and Safety of Losartan/Chlorthalidone vs Losartan/Hydrochlorothiazide in Essential Arterial Hypertension (PHASE3)
- Evaluation of the Antihypertensive Effect of Hyzaar(R) and Cognitive Function of Hypertensive Patients (0954A-322) (PHASE3)
- MK0954A-264 Filter Study (0954A-264)(COMPLETED) (PHASE3)
- HYZAAR vs. Ramipril for Diabetes (0954A-245)(COMPLETED) (PHASE3)
- Evaluate the Safety and Anti-Hypertensive Efficacy of Hyzaar(R) In Patients With Mild To Moderate Essential Hypertension (0954A-323) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- losartan and HCTZ CI brief — competitive landscape report
- losartan and HCTZ updates RSS · CI watch RSS
- InVasc Therapeutics, Inc. portfolio CI